Storys zum Thema Medicale

21.09.2005 – 10:25
ESOT - European Society for Organ Transp
Press Invitation: ESOT 2005 - 12th Congress of the European Society for Organ Transplantation
Geneva (ots) - On behalf of our National Advisory and Local Organising Committees, we extend a warm invitation to you to join us in Switzerland for the 12th ESOT Congress 2005, 16-19 October, in Geneva. Our programme structure proposes the classical form of an international congress, including pre-congress workshops, free paper sessions and plenary sessions. ...
mehr
01.06.2005 – 08:00
Helsinn Healthcare SA
Helsinn Healthcare Licenses a Supportive Care Product from Roche
Biasca, Switzerland (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and ROCHE today announced the signing of a licensing agreement, granting HELSINN HEALTHCARE the worldwide rights for the patented, phase II product, NETUPITANT. Netupitant is a potent and selective NK-1 receptor antagonist, developed as NKE by Roche, for the prevention of chemotherapy-induced nausea and vomiting (CINV). "We are ...
mehr
31.05.2005 – 15:50
Helsinn Healthcare SA
Helsinn Birex Therapeutics Ltd. announces the launch of the new 5-HT3 Receptor Antagonist ALOXI(r) (Palonosetron hydrochloride) EU/1/04/306/001 in Ireland
DUBLIN, IRELAND, May 11th, 2005 - HELSINN BIREX THERAPEUTICS LTD, one of the Irish companies of the Swiss pharmaceutical group Helsinn Healthcare SA, announced today that the company received the first delivery of ALOXI" (palonosetron hydrochloride) from Helsinn Birex Pharmaceuticals LTD, Dublin, on 9th May 2005 ...
mehr
28.02.2005 – 08:00
Helsinn Healthcare SA
Helsinn and Galencia announce a license agreement for Aloxi (Palonosetron) in Greece
LUGANO, SWITZERLAND, and Athens, GREECE (ots) - HELSINN HEALTHCARE SA, a Swiss pharmaceutical group, and GALENICA, a Pharmaceutical company based in Greece, announce the signing of an agreement granting GALENICA the exclusive License and Distribution rights for ALOXI® (Palonosetron hydrochloride) in GREECE. ALOXI® is the second generation of serotonine (5-HT3) ...
mehr
09.12.2004 – 13:32
Austrian Breast and Colorectal Cancer St
Zoledronic Acid Prevents Cancer Treatment-Induced Bone Loss in Breast Cancer Patients Treated with Hormone Therapy
San Antonio, Texas (ots) - - First Data from Large Trial in Premenopausal Women Show Strong Protective Effect Zoledronic acid prevents loss of bone mass caused by adjuvant treatment with an aromatase inhibitor or tamoxifen and the luteinising hormone-releasing hormone analog (LHRHa) goserelin ...
mehr
07.12.2004 – 16:13
Austrian Breast and Colorectal Cancer St
Zoledronic Acid Prevents Cancer Treatment-Induced Bone Loss in Breast Cancer: Patients Treated with Hormone Therapy
San Antonio (ots) - - First Data from Large Trial in Premenopausal Women Show Strong Protective Effect Zoledronic acid prevents loss of bone mass caused by adjuvant treatment with an aromatase inhibitor or tamoxifen and the luteinising hormone-releasing hormone analog (LHRHa) goserelin ...
mehr

08.11.2004 – 07:00
Unilabs SA
Unilabs reaffirms its growth objectives for 2004/2005
During the first quarter, Unilabs laboratories achieved: - revenues of CHF 54.8 million (+4.7%) - EBITDA margin of CHF 6.2 million (+18.6%) - EBIT margin of CHF 4.1 million (+29.3%) Geneva (ots) - During the first quarter of the 2004/2005 fiscal year, which ended on 31 August 2004, Unilabs laboratories achieved consolidated revenues of CHF 54.8 million, up 4.7% as compared to the same prior year period, or 5.1% at ...
mehr
29.07.2004 – 14:09
Baxter International Inc.
Baxter and Cerus Enter Agreement with Asian Partner for Commercialization of Intercept Blood System for Platelets - Agreement to Help Address the Need for a Safer Blood Supply in Asia
DEERFIELD, Ill., and CONCORD, Calif. (ots) - Subsidiaries of Baxter International Inc. (NYSE: BAX) and Cerus Corporation (NASDAQ: CERS) today announced that they have entered into a definitive agreement with BioOne Corporation for commercialization of the INTERCEPT Blood System for platelets in parts of Asia. The ...
mehr
20.07.2004 – 08:17
Unilabs SA
Unilabs signs a new contract for hospital laboratory services
Geneva (ots) - The Unilabs laboratory in Lugano (Tessin) has signed an agreement with two hospital establishments located in the Lugano area. These hospitals comprise a total of 150 beds and accommodate around 6,500 hospitalized patients and 32,000 outpatients per year. The contract, which takes effect immediately, relates to an estimated annual turnover of CHF 1.5 million and a minimum period of until December 31, ...
mehr
09.06.2004 – 07:00
Unilabs SA
UNILABS launches a new range of early-stage diagnostic tests in Europe
Geneva (ots) - Biocheckup tests will allow early detection of signs of illness and permit evaluation of the risk factors for diseases such as diabetes, cancer or cardiovascular disease Most people are concerned by the state of their health and would like to know their predisposition to different pathologies before they become established (e.g. diabetes, cancer, ...
mehr
01.03.2004 – 13:10
Novo Nordisk
Switzerland is first to launch new diabetes therapy - Levemir® (insulin detemir)
Geneva (ots) - Novo Nordisk Switzerland announced today that Levemir® (insulin detemir), a novel, predictable basal insulin analogue with a unique mechanism of prolonging action (scientifically known as protraction), is available for people with type 1 and type 2 diabetes in Switzerland today. The Swiss launch is just the beginning of an exciting global roll-out of ...
mehr
02.02.2004 – 08:00
Juvena of Switzerland
SKIN NOVA TECHNOLOGY - Revolutionizes the World of Cosmetics
Volketswil (ots) - JUVENA of Switzerland is the first cosmetics company world-wide to integrate technology from the field of emergency medicine into skin care products. The basis for this technology is the research work of Professor Odile Damour*, head of the Laboratoire des Substituts Cutanés in Lyon (FR) and authority in the field of biological skin ...
mehr

12.01.2004 – 07:00
Juvena of Switzerland
JUVENA of Switzerland: Emergency Medicine Technology Used in State-of-the-Art Cosmetics
Volketswil (ots) - JUVENA of Switzerland is working side by side with a strong partner: Professor Odile Damour, an authority in the field of natural skin reconstruction. She heads the Laboratoire des Substituts Cutanés of the University of Lyon, one of the leading institutes for the healing of burn related injuries. JUVENA of Switzerland decided at the beginning of ...
mehr
22.08.2003 – 08:17
Antisoma plc
Results Presented From As1403 Phase I Biodistribution Study
London, UK plc (LSE:ASM, NASD-E:ASOM) (ots) - Antisoma announces that results from its phase I biodistribution study of AS1403 (formerly TheraFab) will be presented this weekend to the European Association of Nuclear Medicine meeting in Amsterdam by Dr Michael Garkavij, a leading investigator in the trial. AS1403 is a fragment of the monoclonal antibody HMFG1 linked to a radioactive isotope with cell-killing ...
mehr
22.05.2003 – 08:00
Health Hero Network, Ltd.
Health Hero Network Introduces Disease Management Solutions in Europe at eHealth Conference
Brussels, Belgium (ots) - Universite Louis Pasteur Strasbourg Invited to Demonstrate Health Hero Network Technology at 'The Contribution of ICT to Health' Ministerial Conference and Exhibition 22-23 May -- Brussels Health Hero Network, Ltd. was selected with Universite Louis Pasteur (ULP) Strasbourg to present its Health Buddy(R) in-home health monitoring ...
mehr
03.03.2003 – 09:11
International Herpes Management Forum (I
International Survey Uncovers Need for Improvements in Genital Herpes Management
Paris (ots) - Patient and Physician Insights Presented at International Herpes Management Forum Annual Meeting Many people living with genital herpes are not satisfied with how this common infection is managed, according to the results of a year-long international survey of patients and physicians presented at this weekend's 10th Annual Meeting of the ...
mehr
28.01.2003 – 08:15
Ektron
Ektron Adds New Scalability Features to its Web Content Management Solutions, Including Support for Microsoft® Active Directory and Load Balancing
AMHERST, NH/USA (ots) - With Enterprise-Class Features, Ektron CMS200 and CMS300 Continue to Offer "Lowest Total Cost Of Ownership" Among Mid-Tier CMS Solutions Ektron today unveiled features that enhance flexibility and scalability of Ektron CMS200 and Ektron CMS300, including new support for Microsoft® ...
mehr
25.10.2002 – 20:07
The Business Humanitarian Forum
Workshop Highlights Successful Prevention in Africa of Mother-to-Child Transmission of HIV/AIDS
Geneva (ots) - Under the aegis of The Business Humanitarian Forum, representatives from businesses, United Nations system agencies, and foundations gathered this afternoon for a workshop entitled "Combating the HIV/AIDS Epidemic in Africa: Mother to Child Transmission Prevention". The participants discussed ...
mehr

24.10.2002 – 08:25
IREF-Ischemia Research and Education Fou
Aspirin shown to greatly reduce death and suffering from Ischemic Complications following heart bypass surgery
SAN FRANCISCO, CA (ots) - Landmark study published in the New England Journal of Medicine identifies safe, inexpensive therapy to save lives and healthcare costs Led by Dr. Dennis T. Mangano and the Ischemia Research & Education Foundation, a massive, worldwide study involving 17 countries, 70 medical ...
mehr
23.08.2002 – 08:24
Nat. Council of State Boards Nursing
International Administration Of The NCLEX(R) Considered At NCSBN Delegate Assembly
CHICAGO, IL (ots) - The National Council of State Boards of Nursing (NCSBN) (www.ncsbn.org) recently approved a recommendation from its Examination Committee to proceed with negotiations for a contract amendment with its test service vendor (Pearson, plc.) for purposes of international administration of the NCLEX(R) examinations. At its 2002 Delegate Assembly (held ...
mehr
09.08.2002 – 09:25
Karolinska Institute, Stockholm
Subcutaneous MabCampath(R)/Campath(R) Highly Effective In Previously Untreated CLL Patients
Stockholm, Sweden (ots) - Subcutaneous administration of the first and only monoclonal antibody, MabCampath(R)/Campath(R) (alemtuzumab), approved for treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (B-CLL) patients (33 percent response), elicited an overall response of 87 percent in ...
mehr
18.04.2002 – 07:15
Novartis International AG
Novartis continues on dynamic growth path as Pharmaceuticals increases market share
Basel (ots) - * First-quarter Group sales up 13% in local currencies (10% in Swiss francs) * Pharmaceuticals extends double-digit sales growth (+16% in local currencies; +14% in Swiss francs), driven by strong demand for cardiovascular, oncology and ophthalmic products in all regions * Net profits surge ...
mehr
07.11.2001 – 14:34
Drägerwerk AG & Co. KGaA
Draeger's upswing continues
Q3/2001 once more with definite sales and earnings gains Safety Technology strong Medical Technology reaping restructuring benefits Luebeck, Germany (ots) - With 9-month sales and earnings buoyant, Luebeck-based Draegerwerk AG is progressing well along the turnaround road leading to its back-to-the-black destination for 2001. As announced by this Medical & Safety Technology Group, consolidated three-quarter sales advanced by 13.6 percent to Euros 825.6 million (up ...
mehr
02.11.2001 – 12:58
ScheBo(R) Biotech AG
The Forgotten Organ - Why to Screen for Exocrine Pancreatic Malfunction with respect to Diabetes Mellitus! / Tumour Metabolism - A Novel Concept Closes a Clinical Gap!
Giessen, Germany (ots) - Diabetes mellitus and cancer are among the diseases of greatest clinical focus. At the ScheBo Biotech AG Symposium during MEDICA on the occasion of the World Congress of Pathology and Laboratory Medicine (WASPaLM) 2001 two specific diagnostic tools with unique clinical approaches will be ...
mehr

Vorherige39404142434445464748